ClearPoint Neuro: Biopharma Momentum Continues To Build

ClearPoint Neuro's (NASDAQ: CLPT ) second quarter results were solid, with each of the company's segments expanding. The results may be considered disappointing by some investors though, due to modest system placements and ongoing losses. This is not particularly concerning though, given that ClearPointRichard Durant is the leader of Narweena, an asset manager focused on finding market dislocations that are the result of a poor understanding of a businesses long-term prospects. Narweena believes that excess ...